Experts explain how to adapt after myeloma relapse - myeloma relapse

A relapse of multiple myeloma often marks a critical juncture for patients and their care teams, prompting a reassessment of treatment strategies and expectations. The disease frequently returns even after initial therapies achieve control. Experts clarify that this recurrence does not indicate the first treatment failed, but rather reflects the unpredictable nature of myeloma itself.

Tulio Rodriguez, a hematologist-oncologist and director of the Bone Marrow Transplant and Cellular Therapy Program at City of Hope Cancer Center Chicago, explains that myeloma can remain dormant for years before resurfacing, regardless of how well it initially responded to treatment. “Myeloma is a disease that we can often control for long periods of time, but it can evolve and return despite an excellent response to therapy,” he states.

Amrita Krishnan, executive medical director of hematology at City of Hope Orange County, reinforces this point, noting that prolonged remissions are possible. A relapse instead signals the need for a revised treatment strategy rather than a judgment on prior care. Rodriguez emphasizes that the goal remains adapting therapy to maximize patient benefit.

Patients often adjust their treatment objectives while exploring newer options. The fundamental aims—prolonging survival, preserving quality of life, and controlling the disease—remain unchanged, though the methods to achieve them must evolve. Rodriguez outlines the decision-making process: evaluating how the disease responded to previous therapies, the duration of those responses, the patient’s overall health, and any newly available treatment options. “We look at how the disease responded to prior therapies, how long that response lasted, the patient’s overall health, and any new treatment options that may now be available,” he says.

New therapies now start earlier

Recent years have brought significant advancements in myeloma treatment, particularly the earlier adoption of aggressive therapies like CAR T-cell therapy and bispecific antibodies. These options, once limited to later stages, are now considered sooner in the treatment timeline. Rodriguez attributes this shift to patients entering treatment in better health, making them suitable candidates for intensive interventions. “We focus on matching the best treatment to the right patient at the right time,” he explains.

Not all patients benefit equally from the most advanced treatments. Krishnan warns that individual health, disease characteristics, and personal priorities determine suitability. Some may seek deep, lasting responses, while others prioritize minimizing side effects or reducing treatment duration. Before decisions are made, patients should discuss their goals with their care team, considering questions such as treatment objectives, likelihood of success, expected side effects, daily life impacts, and contingency plans if the therapy fails.

Publicly available survival statistics can be misleading. Rodriguez cautions that population-based data does not account for individual variations in health, disease biology, or access to newer therapies. Krishnan adds that many online figures reflect outcomes from eras when current treatments were unavailable. Real-world experiences therefore vary widely based on these factors.

Personalized plans after relapse

After a relapse, treatment becomes increasingly personalized. Krishnan stresses that no two cases are identical, with decisions hinging on relapse speed, prior therapies, and patient preferences. “We consider how quickly the myeloma returned, which treatments the patient has already received, how well they worked, and what side effects the patient experienced.” This collaborative approach ensures care aligns with both medical evidence and personal values.

Clinical trials offer access to experimental therapies not yet widely available. Rodriguez notes that these studies often provide treatments showing early promise, including novel drug combinations or entirely new classes. For patients resistant to standard therapies, trials may represent the only viable path to remission.

Trials also refine how treatments are matched to disease biology. Krishnan explains that genetic testing now identifies mutations driving relapse. These insights enable more precise prescribing, reducing trial-and-error cycles. Patients with relapsed disease after multiple prior treatments have achieved lasting responses through trials testing bispecific antibodies or antibody-drug conjugates designed to overcome resistance.